Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80.7M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
-4.8M
-
Total reported value, excl. options
-
$78.3M
-
Value change
-
-$14.2M
-
Put/Call ratio
-
0.39
-
Number of buys
-
43
-
Number of sells
-
-59
-
Price
-
$2.60
Significant Holders of Altimmune, Inc. - Common Stock (ALT) as of Q3 2023
139 filings reported holding ALT - Altimmune, Inc. - Common Stock as of Q3 2023.
Altimmune, Inc. - Common Stock (ALT) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 80.7M outstanding shares and own 37.32% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.79M shares), Nuveen Asset Management, LLC (3.45M shares), VANGUARD GROUP INC (3.34M shares), TANG CAPITAL MANAGEMENT LLC (2.75M shares), MARSHALL WACE, LLP (1.8M shares), Avidity Partners Management LP (1.16M shares), GEODE CAPITAL MANAGEMENT, LLC (1.05M shares), ARDSLEY ADVISORY PARTNERS LP (992K shares), Balyasny Asset Management L.P. (948K shares), and TWO SIGMA ADVISERS, LP (937K shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.